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Enantiomerically pure 1-(6-methoxynaphth-2-yl) and 1-(6-(dimethylamino)naphth-2-yl) carbinols are
fluorogenic substrates for aldo/keto reductase (KRED) enzymes, which allow the highly sensitive and reli-
able determination of activity and kinetic constants of known and unknown enzymes, as well as an
immediate enantioselectivity typing. Because of its simplicity in microtiter plate format, the assay qual-
ifies for the discovery of novel KREDs of yet unknown specificity among this vast enzyme superfamily.
The suitability of this approach for enzyme typing is illustrated by an exemplary screening of a large col-
lection of short-chain dehydrogenase/reductase (SDR) enzymes arrayed from a metagenomic approach.
We believe that this assay format should match well the pharmaceutical industry’s demand for acetophe-
none-type substrates and the continuing interest in new enzymes with broad substrate promiscuity for
the synthesis of chiral, non-racemic carbinols.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Biocatalysis offers excellent opportunities for the synthesis of
chiral compounds in a non-racemic fashion.1 Complementary to
chemical synthesis or kinetic resolution of racemates, enzyme cat-
alyzed direct asymmetric synthesis is a highly efficient technology,
for example for the preparation of chiral alcohols, chiral amines, or
chiral ketone derivatives by ketone reductions using carbonyl
reductases,2 reductive aminations using transaminases3 or carboli-
gations using aldolases4 or transketolases,5 respectively, in up to
100% optical purity and 100% yield. Particularly, NAD(P)H depen-
dent ketoreductases (KREDs) are a well-established and reliable
source of chiral alcohols with high enantiomeric purity, which
are of importance as chiral building blocks for the production of
pharmaceutical intermediates (Fig. 1).6
While the application of baker’s yeast and related whole cell
catalysts is attractive for the low costs,8 most organisms were
found to follow Prelog’s rule in producing predominantly the (S)-
configured products.9 In addition, microbial cells typically contain
multiple enzymes having potentially conflicting specificities, thus
eroding product yields and enantiomeric excess. The advent of lar-
ger commercial collections of recombinant KREDs significantlyfacilitates the identification of an appropriate catalyst for the con-
version of a specific substrate. Discovery of new KREDs from vari-
ous sources, such as for less common enzymes with anti-Prelog
selectivity,10 can be pursued in various ways. This includes theo-
retical approaches in silico such as data mining from recent whole
genome sequencing, and experimental approaches in vitro such as
screening in culture collections or in metagenomic campaigns, as
well as rational engineering or directed evolution of known
enzyme scaffolds.
A decisive factor for the further development of this platform
technology is the ability for rapid identification of enzymes having
high activity and high stereoselectivity for the desired product con-
figuration. This is usually performed by screening for activity to
reduce the ketone substrate, followed by determination of product
alcohol configuration and enantiomeric excess using chiral chro-
matographic techniques (GC, HPLC), which can only be performed
in a tedious serial fashion and are expensive. As most ketone
reductions do not produce readily detectable changes in UV/VIS
absorption or fluorescence of the product, the conversion is usually
followed using either the associated depletion of reduced nicoti-
namide cofactor by UV (e340 nm = 6 300 M1 cm1), or by coupling
redox cofactor recycling to a secondary product that can be moni-
tored colorimetrically (e.g. INT-formazan; e492 nm = 19 900 M1 -
cm1).11 However, significantly higher sensitivity and specificity
are attainable by measurement of fluorescence emission rather
than UV/VIS absorption.12 Fluorogenic enzyme substrates are
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Fig. 1. Chiral pharmaceutical intermediates produced on large scale using KRED
catalysis.7
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directly related to the enzyme-catalyzed reaction. Thus, a fluoro-
metric assay for the discrimination of human alcohol dehydroge-
nase isoenzymes has been developed based on the consumption
of fluorescent naphthaldehydes as reporter substrates.13 An indi-
rect assay has been published by which a chiral secondary alcohol
is oxidized to produce a ketone, which subsequently undergoes b-
elimination in the presence of bovine serum albumin to release
umbelliferone;14 however, because the blue fluorescent phenolate
anion needs a shift to alkaline pH, the assay is not amenable to con-
tinuous kinetic measurements. To the best of our knowledge, no
direct stereoselective fluorescence assay for measuring KRED activ-
ity has been reported.
Here we report on the development of a direct fluorogenic assay
format, which allows the rapid and highly sensitive quantification
of enzyme activity in a high-throughput fashion in a highly parallel
microtiter plate format. The assay can be used for simultaneous
Prelog stereospecificity typing as well as the determination of the
level of enantioselectivity of KRED enzymes in one step. The assay
concept further allows a systematic modular variation of the sub-
strate structure to facilitate a substrate morphing approach4a for
protein engineering projects.2. Results and discussion
2.1. Assay principle
KREDs are nicotinamide cofactor-depending enzymes that
reduce ketones into chiral secondary alcohols and vice versa.15 In
the reverse mode, the carbinol functionality reacts by hydride
transfer to NAD(P)+ with formation of NAD(P)H and release of a
ketone. Substituted acetophenones comprise one of the most
important substrate classes, for which most KREDs have been
found to be active against, many exhibiting high stereoselectiv-
ity.8b When the non-fluorescent 1-(6-methoxynaphth-2-yl)
ethanol 1a (R = CH3) in the appropriate enantiomeric form acts as
a KRED substrate, the corresponding acetonaphthone derivative
2a would be formed, which shows a bright blue fluorescenceR
OH
MeO
R
O
MeO
KRED
1 2
NAD(P)+ NAD(P)H
Scheme 1. Fluorogenic assay principle for KREDs with release of the fluorescent
ketone 2 upon oxidation of a chiral benzylic alcohol 1.
Please cite this article in press as: Thai Y.-C., et al. Bioorg. Med. Chem. (2017),emission around 460 nm with quantum yield of about 0.2 that
can be readily detected using a common plate reader (Scheme 1).
Recently, we have developed a similar fluorogenic assay for
transaminases based on the corresponding chiral amine, from
which the same ketone is liberated upon transaminase
catalysis.16 It is interesting to note that substrate rac-1a very
recently has also been used in a confocal microscopic study to
localize redox enzymes in the yeast Candida parapsilosis by occur-
rence of fluorescence upon oxidative generation of ketone 2a.17
2.2. Substrate synthesis and resolution
For the synthesis of racemic alcohols 1 we recently described a
modular approach comprising a Grignard addition to the commer-
cial aldehyde 3 (Scheme 2),16 which directly furnishes the desired
compounds for KRED assays. In addition, the individual carbinol 1a
was prepared by standard borohydride reduction of the commer-
cial ketone 2a.18 This synthetic strategy rapidly provides access
to a family of assay compounds that can be precisely designed by
selecting an appropriate Grignard reagent for introducing a broad
variety of structural variations in the R group, which should facil-
itate an incremental sculpting of the small binding pocket of a
given target KRED scaffold. Besides being highly efficient because
of its modular nature, this synthesis also avoids the need for
tedious separation of regioisomeric 6-methoxy-acylnaphthalenes,
which are obtained by Friedel-Crafts acylation.19
Enantiomers of 1a were kinetically resolved by lipase-catalyzed
transacylation in vinyl acetate using immobilized lipase B from
Candida antarctica (CAL-B) according to literature precedent.20
Both antipodes of the carbinol were obtained with >99% ee (HPLC
analysis) in excellent yield, including the deprotection of the ester
(R)-4a. Configurational assignments follow the general predictions
of Kazlauskas rule.21
2.3. Assay development
Orienting tests performed with commercial yeast alcohol dehy-
drogenase (YADH) and horse liver alcohol dehydrogenase (HLADH)
proved negative, apparently the acetonaphthone moiety being too
bulky to enter the substrate-binding sites. However, when racemic
1a was incubated with the (R)-selective KRED from Lactobacillus
brevis in the presence of its preferred cofactor NADP+ at an opti-
mum pH of 7.5, the development of the bright blue fluorescence
of ketone 2a could be monitored against background, verifying
the general assay concept. These experiments also indicated that
the extended naphthyl fluorophore structure is instrumental in
effectively discriminating enzymes that are substrate tolerant
(e.g. the KRED from L. brevis) from those having a rather narrow
specificity for smaller substrates (e.g. YADH and HLADH enzymes).
Indeed, the L. brevis KRED has previously been shown to have a
broad substrate tolerance,22 in particular being highly adaptive to
bulky substrates including substituted acetophenones.23 This
broad scope as well as its high stability and stereoselectivity make
the enzyme very attractive for industrial applications.24 The X-ray
protein crystal structure has been solved to atomic resolution,
including a ternary complex with nicotinamide cofactor and sub-
strate (R)-1-phenyl ethanol bound to the active site.25 Inspection
of its structure indicates that the substrate binding site has a nar-
row pocket at the bottom of the groove, which binds the small
alkyl moiety of an (R)-configured methyl carbinol, while the arene
unit makes several hydrophobic contacts to side-chains but points
towards the entrance of the active site.25b The latter appears to be
wide enough to also accommodate the substituted naphthyl
moiety of the fluorogenic substrate (R)-1a.
Despite its polar hydroxyl function substrate 1a is only spar-
ingly soluble in plain water and must be applied from concentratedhttp://dx.doi.org/10.1016/j.bmc.2017.05.024
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Scheme 2. Synthesis of substrate alcohols 1a–c and racemate resolution of 1a by lipase catalyzed transacylation.
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tion of 15% DMSO gave clear solutions containing up to 1.0 mM
substrate 1a or ketone 2a that generated a consistent data quality
in liquid assays. KRED enzymes require nicotinamide cofactors in
stoichiometric quantities or a suitable in situ recycling system. In
direction of oxidation, NAD(P)+ recycling is typically achieved by
either substrate-coupling in the presence of a sacrificial ketone,
which thereby is reduced to the corresponding secondary alcohol,
or by enzyme-coupling such as with the lactate dehydrogenase/
pyruvate system.26 For several reasons we decided on the sub-
strate-coupling option with acetone as co-substrate, which takes
advantage of the ability of many KREDs to react with small ketone
substrates, and because conversion to isopropanol does not induce
pH changes that are typically observed for enzyme-coupled
approaches; also no extra enzyme is needed. An additional benefit
is the fact that acetone can assist as a co-solvent to solubilize the
substrate and usually is well tolerated by enzymes at concentra-
tions of 10% or even higher.27 An enzyme identified by this new
procedure in turn will offer an economical advantage with respect
to the necessity for cofactor recycling when planning preparative
applications on larger scale.28
Considering the fluorescence spectrum of ketone 2a in water,
kinetic measurements were performed with excitation at 330 nm
(kmax = 312 nm) and emission observed at 460 nm (kmax = 441 -
nm).18 The ketone shows a linear fluorescence increase with rising
concentration, which allows continuous quantification of enzyme
activity by correlation with a standard curve. The limit of detection
(LOD) and limit of quantification (LOQ) values derived by linear
regression to characterize the performance of the assay were
0.35 nmol/min and 1.2 nmol/min (vmax for 2a), respectively.29 In
order to shift the reaction equilibrium towards target ketone 2a
synthesis, assays were run under slightly alkaline conditions (pH
7.5), in the presence of the natural nicotinamide cofactor mixture
present in the cell-free extract.
Resultant time curves for appearance of fluorescence due to for-
mation of ketone 2a showed excellent linearity, and varying the
amount of protein confirmed a good correlation between signal
intensity and enzyme activity (Figs. S3, S4). No fluorescence signal
was recorded in either the absence of the biocatalyst or co-sub-
strate, as long as no additional NAD(P)+ cofactor was added (which
could act as a co-substrate) beyond that bound to the enzyme
active site. Measurements were tested in microtiter plate format
with good reproducibility against parallel standard dilutions.
Reaction rates were easily determined even for concentrations
of alcohol 1a as low as 100 lM and short reaction times (20 min)Please cite this article in press as: Thai Y.-C., et al. Bioorg. Med. Chem. (2017),with good linearity between substrate concentration and signal
intensity (Fig. S3). When the KRED from L. brevis was exposed to
pure substrate enantiomers, only the (R)-1a isomer gave rise to flu-
orescence development while the opposite (S)-1a isomer did not
react, even over extended reaction times (<1% activity). This con-
firms reports for acetophenone-type reductions that this enzyme
has a high discrimination in the specificity constants kcat/KM for
individual enantiomers,22a,23a or an excellent kinetic E-factor (or
enantioselectivity).30 For (R)-1a the L. brevis KRED showed Michae-
lis-Menten-type kinetics with a KM = 0.30 mM in the presence of
15% DMSO (Fig. S6).
Although we have not yet explored the option for measuring
the influence of further reaction parameters that might have an
influence on enzyme activity, such as pH, temperature or addition
of other co-solvents, it appears to be a rather simple task to study
enzyme properties by serial variation of any such effectors or phys-
ical parameters under the standard assay conditions. Especially,
the replacement of the co-substrate acetone by other (non-fluores-
cent) ketones or aldehydes as alternatives for the required in situ
cofactor recycling seems a promising option to further determine
the substrate specificity of a given KRED by using the otherwise
identical, highly sensitive detection method.
In order to evaluate and validate the assay for its potential in
high-throughput screening applications, we further determined
the Z-factor,31 a dimensionless statistical parameter that reflects
both the assay signal dynamic range and the data variation associ-
ated with the signal measurements. For a substrate concentration
of 0.8 mM we determined an excellent Z-factor of 0.90, whereas
even at lower substrate concentration of 0.2 mM a very high Z-fac-
tor of 0.72 resulted. Thus, the fluorogenic assay seems to be very
appropriate for screening efforts of variant libraries in the directed
evolution of KREDs with improved or altered protein properties,
while consuming only very small substrate quantities (e.g.,
0.5 mg of 1a per 96-well microtiter plate at 0.25 mM substrate
concentration).
2.4. Typing of novel KRED enzymes
As an exemplary application of the new assay we attempted to
identify active KRED hits among a commercial collection of aldo/
ketoreductase enzymes arrayed in 96-well plate format (Prozomix
Ltd) by exposure to the rac-1a substrate under the optimized con-
ditions (0.25 mM, 5% acetone, 90 min). The enzymes were
recruited by a metagenomic approach employing environmental
samples from the UK and are classified as belonging to the short-http://dx.doi.org/10.1016/j.bmc.2017.05.024
4 Y.-C. Thai et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxxchain dehydrogenases/reductases (SDR) type. SDR enzymes consti-
tute one of the largest protein superfamilies known today, most of
which are NAD(P)H-dependent oxidoreductases.32 SDRs present a
common three-dimensional structure featuring an N-terminal
Rossmann-fold motif for nucleotide binding. They form a large,
functionally heterogeneous protein family that displays a wide
substrate spectrum, including steroids, alcohols, sugars, aromatic
compounds, and xenobiotics. When we discovered that indeed a
high fraction of biocatalysts in this SDR collection proved active
on the sterically demanding substrate 1a, we conducted an enan-
tioselectivity typing of these enzymes by applying the individual
enantiomers (S)-1a and (R)-1a under the same conditions
(Fig. 2A). The corresponding activity data allow calculating a rough
estimate for the enantioselectivity of the KRED panelists before
determining exact specificity constants.
Interestingly, while the most active candidate (G03 = KRED363)
in the specific collection examined reached up to 90% total sub-
strate conversion, more than half of the enzymes (53/96) caused
at least 10% relative conversion, and more than one quarter
(27/96) even reached at least 50% conversion, with either substrate
enantiomer. Concerning their enantiopreference, (S)-selective Pre-
log-type enzymes were by far predominating (42/96; almost 80%
of active catalysts), with very few enzymes showing anti-Prelog
(R)-specificity (2/96;<4% of active catalysts); some fraction of the
enzymes (9/96; 17% of active catalysts) showed only low enantios-
electivity because they had ambiguous activity with both substrate
enantiomers.
For an assay validation, in addition to the (R)-selective KRED
from L. brevis one representative hit of an (S)-selective (plate entry
A12 = KRED(00300)) and non-stereoselective SDR (plate entry
B03 = KRED(00303)) were expressed in E. coli, purified by NTA
chromatography and re-evaluated with respect to their enantiose-
lectivity. In each case, the stereopreference could be unequivocally
confirmed. All enzymes showed Michaelis-Menten-type kinetics
with high substrate affinity (e.g., KM = 0.076 mM of KRED(00300)
for substrate (S)-1a and 0.025 mM of KRED(00303) for substrate
(R)-1a).
An attempt to correlate the activity and stereoselectivity data
with a phylogenetic analysis of the SDR panel revealed thatA)
B)
Fig. 2. A) Exemplary screening of a highly diverse metagenomic short-chain dehydrogen
(00289–00384)), by using individual enantiomers (S)-1a and (R)-1a ( and , respectivel
against a fluorescence standard curve measured with ketone 2a under identical assay c
Please cite this article in press as: Thai Y.-C., et al. Bioorg. Med. Chem. (2017),properties were spread throughout the respective protein family
(PF00106) without any clear pattern (Fig. 3). This result empha-
sizes the need for novel assays to rapidly characterize novel KREDs
experimentally as their stereo-preference cannot be predicted by
genetic cluster analysis alone, even within the primary sequence
boundaries of an individual pfam.
We also conducted an exemplary test to evaluate the potential
of the fluorogenic assay method to determine the substrate toler-
ance of individual KRED enzymes. For this purpose, the arrayed
panel was probed against the homologous propyl carbinol sub-
strate rac-1b (Fig. 2B).16 When compared to the activity with sub-
strate 1a carrying the smallest methyl substituent, interestingly
the carbinol 1b having a larger alkyl moiety was converted by
about one fifth of all enzymes (20/96), or more than one third of
the active catalysts (20/53) with a relative velocity of >10%, indi-
cating that many catalyst in the SDR category will offer an interest-
ing substrate promiscuity. Still, the majority of the active enzymes
in the SDR panel seems to have a rather small pocket for adapting
only a methyl moiety. Particularly, the option for systematic struc-
tural variation of the substrate by altering the R group in the mod-
ular synthesis of carbinols 1 should be a valuable asset to probe
and expand the small substrate pocket of a selected KRED by pro-
tein engineering, if directed at residues building up the small sub-
strate binding pocket. The potential utility of such a biocatalyst
engineering approach is supported by the observation that when
challenged with the benzyl derivative rac-1c, an example of a sub-
strate carrying two very bulky moieties next to the reaction site,
however none of the native SDRs in the selected panel showed
detectable activity.
2.5. Sensitivity improvement
The assay principle is based on the blue fluorescence emission
of the methoxy substituted ketone 2, for which a certain limitation
might be seen in the incomplete quantum yield and the potential
interference of the UV irradiation wavelength with other photoac-
tive components in the assay solution, e.g. when using crude cell
extracts. In order to enhance the sensitivity of signal detection,
we also tested the corresponding acedan system (Scheme 3),ase/reductase (SDR) array in 96-well plate format (Prozomix Ltd, Cat No.s PRO-KRED
y). Maximum substrate conversion after 1.5 h was 90% as determined by comparison
onditions. B) Screening of the same plate by using rac-1b as substrate ( ).
http://dx.doi.org/10.1016/j.bmc.2017.05.024
Fig. 4. Exemplary fluorogenic screening of a KRED array in 96-well plate format
(Prozomix Ltd, Cat No.s PRO-KRED(00289-00384)) against rac-5a.
Fig. 3. Phylogenetic analysis for the novel and primary sequence diverse metage-
nomic SDR array (Fig. 2) showing a correlation of the enantiospecificity for the most
active enzymes ( > 40% rel. activity). Highly (S)-selective and (R)-selective enzymes
( > 90% selectivity) are color coded as in Fig. 2, while non-stereoselective ones
( < 90% selectivity) are shown in magenta.
LiNMe2
DMPU/THF-hexane
24 h, r.t.
rac-5a
Me2N
OH
Me2N
O
KRED
NAD(P)+
green fluorescence
H3CO
O
2a
6a
NaBH4, MeOH
blue fluorescence
Scheme 3. Synthesis of substrate alcohol 5a for KRED activity screening with
higher sensitivity due to longer wavelength fluorescence emission.
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dimethylamino group (6a). The latter not only causes a shift ofPlease cite this article in press as: Thai Y.-C., et al. Bioorg. Med. Chem. (2017),the fluorescence emission towards a longer green wavelength
(kabs = 362 nm and kem = 524 nm)18 but also significantly improves
upon the fluorescence brightness (e UF = 2240). The synthesis of
6a was first pursued via the phenol derived from 2a by using the
Bucherer reaction,33 which suffered from incomplete conversion
and separation problems. Much preferred is the direct substitution
according to a modified literature procedure using LiNMe2 in
DMPU.34 Following borohydride reduction of ketone 6a, the result-
ing carbinol rac-5a could then be easily resolved into its enan-
tiomers (S)-5a and (R)-5a by CAL-B catalyzed transacylation in
analogy to the separation of methoxy compound rac-1a
(Scheme 2).
Although substrate 5a itself is fluorescent with emission in the
blue range of the visible spectrum, there is no overlap with the
long-wavelength green emission of ketone 6a. Signal development
was recorded at 520 nm without background interference. For an
exemplary test, compound rac-5a was thus applied to the fluoro-
genic screening of the same diverse SDR array in 96-well plate for-
mat (Fig. 4), using the same conditions previously developed for
the application of 1a. For (R)-5a the KRED from L. brevis showed
a high substrate affinity (KM = 0.22 mM), which is almost identical
to that for (R)-1a (Fig. S7).3. Conclusion and outlook
The generation of brightly fluorescent acetonaphthone deriva-
tives 2 and 6 from chiral 1-(6-methoxynaphth-2-yl)carbinols 1
and its 6-dimethylamino analog 5, respectively, is a new principle
to prospect for useful KRED catalysis. We demonstrated that this
new assay format is applicable to the reliable determination of
activity and kinetic constants of known and unknown enzymes.
When employing enantiomerically pure individual antipodes of
carbinols 1a/5a, the method allows for the rapid and immediate
and cost-effective enantioselectivity typing of enzymes. The assay
is characterized by high sensitivity in microtiter plate format,
which qualifies for the discovery of novel KREDs of yet unknown
specificity among this vast enzyme superfamily. The suitability of
this approach for enzyme typing was confirmed by an exemplary
screening of a large collection of SDR enzymes arrayed from a
metagenomic approach. We believe that this assay format should
match well the pharmaceutical industry’s demand for acetophe-
none-type substrates and the continuing interest in new enzymes
with broad substrate promiscuity, particularly those tolerating
bulky substituents, for the synthesis of chiral, non-racemic carbi-
nols. We note that our fluorogenic assay also avoids problems from
an interference of UV absorbing pharmaceutical intermediates
with conventional NAD(P)H dependent measurements.http://dx.doi.org/10.1016/j.bmc.2017.05.024
6 Y.-C. Thai et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxxIts simplicity and low substrate consumption renders the assay
particularly suitable for large-scale liquid screening campaigns in
the directed evolution of optimized KREDs. The latter purpose is
facilitated by the modular scheme of substrate synthesis that
allows a simple and rapid generation of broad structural variations
in the acyl/carbinol moiety, required in particular for a targeted
adaptation of the small substrate-binding pocket. Not least, such
discovery and optimization of desired KREDs is also important
for the integration of redox conversion modules into advanced
reaction cascades along the concept of Systems Biocatalysis.354. Experimental section
4.1. Fluorogenic assay set-up and determination of kinetic constants
The assay was developed in Sarsted 96-well plates using a BMG
Optima plate reader equipped with 330 nm filters for excitation
and 460 nm filters for emission. The standard curve of the assay
was determined by using a dilution series of the ketone 2a and
6a in a concentration range of 0.0–1.0 mM in the corresponding
assay buffer. Different enzyme-substrate pairs were measured as
triplicates using a serial dilution of 0.0–3.0 mg mL1 of the ADH
from Lactobacillus brevis (lyophilized cell free extract in 50 mM
phosphate buffer, pH 7.5). Each well contained 30 mL substrate
stock in a 2:1 mixture of DMSO and acetone, 40 mL enzyme stock
and 130 mL phosphate buffer (50 mM, pH 7.5).
Kinetic constants were calculated by varying the substrate con-
centration of (R)-1a and (R)-5a between 0.0 and 1.0 mM using a
fixed enzyme concentration. Each well contained 0–30 mL sub-
strate stock in a 2:1 mixture of DMSO and acetone, 30–0 mL of a
DMSO–acetone mixture, 40 mL enzyme stock and 130 mL phosphate
buffer (50 mM, pH 7.5). All measurements were performed in trip-
licate at 30 C. Raw data were exported to MS Excel and were pro-
cessed with Origin 9.1 for hyperbolic fitting.
LOD and LOQ were determined for both 2a and 6a. Assay reac-
tion was performed using ADH from L. brevis cell free extract
(200 lg per well) for incubation of substrate (R)-1a at 0.5 mM con-
centration and negative control without substrate. All data were
measured as triplicates. The LOD was defined as LOD = 3.3 r/S
and LOQ was defined as LOQ = 10 r/S, where r is the standard
deviation of the control and S is the slope of the standard curve.
They were calculated for LOD = 6 lM and 1.7 lM, LOQ = 18 lM
and 5 lM for 2a and 6a, respectively.4.2. Microplate screening assays using commercial plate
Preparation of screening plates for KRED enzymes was per-
formed as described.11 Plates were kept frozen at -20 C for storage
until use. Using the cross-hairs in the microplate sealing film as a
guide, 100 mL of an aq 0.25 mM solution of enantiomerically pure
(R)-1a or (S)-1a containing 5% DMSO and 5% acetone were added
to each well of the microplate (Prozomix Ltd, Cat No.s PRO-KRED
(00289-00384)) using a multi-channel pipette. The contents were
mixed carefully to dissolve the freeze-dried enzyme pellets. The
plates were briefly shaken on a plate shaker, then pulse cen-
trifuged, followed by removal of the cross-hair film before the
kinetic analysis using a microplate reader.4.3. Screening for substrate promiscuity
The microplate was tested using the assay conditions as
described above but replacing the substrate with 1-(6-methoxy-
naphthalen-2-yl)butanol rac-1b or 1-(6-methoxynaphthalen-2-
yl)-2-phenylethanol rac-1c.Please cite this article in press as: Thai Y.-C., et al. Bioorg. Med. Chem. (2017),Acknowledgements
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